Molecular mechanisms of ursodeoxycholic acid toxicity & side effects: Ursodeoxycholic acid freezes regeneration & induces hibernation mode

International Journal of Molecular Sciences

Volumn 13, Issue 7, 2012, Pages 8882-8914

  Kotb, Magd A ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

Extrahepatic biliary atresia; Neonatal cholestasis; Neonatal hepatitis; Primary biliary cirrhosis; Primary sclerosing cholangitis; PSC; Side effects; Toxicity; Ursodeoxycholic acid; Vanishing bile duct syndrome

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; COENZYME A; CORTICOSTEROID; CYCLIC AMP; FIRTECAN; LITHOCHOLIC ACID; NITRIC OXIDE SYNTHASE; PLACEBO; PROTEIN P53; URSODEOXYCHOLIC ACID; CHOLAGOGUE; TP53 PROTEIN, HUMAN;

ABSCESS; ANTIPROLIFERATIVE ACTIVITY; ASCITES; BILE DUCT DISEASE; BREAST CANCER; BRONCHITIS; BRONCHOPNEUMONIA; CELL REGENERATION; CHOLANGITIS; CHOLESTASIS; CHRONIC LIVER DISEASE; COLORECTAL TUMOR; CONVULSION; CYSTIC FIBROSIS; DIABETES MELLITUS; DIARRHEA; DNA REPAIR; DNA STRAND BREAKAGE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CONJUGATION; DRUG CYTOTOXICITY; DRUG DETOXIFICATION; DRUG ERUPTION; DRUG EXCRETION; DRUG FATALITY; DRUG FEVER; DRUG HALF LIFE; DRUG METABOLISM; DRUG STRUCTURE; DRUG TISSUE LEVEL; DYSURIA; GALLSTONE; GENOTOXICITY; HEPATITIS B; HEPATITIS C; HUMAN; HYDROPHILICITY; HYPERBILIRUBINEMIA; IMMUNE DEFICIENCY; IMMUNOMODULATION; INTERSTITIAL LUNG DISEASE; INTERSTITIAL NEPHRITIS; LEUKOCYTOCLASTIC VASCULITIS; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER PROTECTION; LIVER TOXICITY; LIVER TRANSPLANTATION; MICROGLIA; MUTAGENIC ACTIVITY; NAUSEA; NONALCOHOLIC FATTY LIVER; NONHUMAN; OTITIS MEDIA; PHAGOCYTOSIS; PHARYNGITIS; PNEUMONIA; PORTAL HYPERTENSION; PRIMARY BILIARY CIRRHOSIS; PRIMARY SCLEROSING CHOLANGITIS; PROGNOSIS; PRURITUS; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SLEEP DISORDER; THROMBOCYTOPENIA; THRUSH; TOXIC HEPATITIS; VANISHING BILE DUCT SYNDROME; VOMITING; WEIGHT GAIN; WHEEZING; WITHDRAWAL SYNDROME; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; LIVER CIRRHOSIS, BILIARY; LIVER REGENERATION; LIVER TUMOR; METABOLISM; PATHOLOGY;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CHOLAGOGUES AND CHOLERETICS; COENZYME A; CYCLIC AMP; DNA REPAIR; HUMANS; LIVER CIRRHOSIS, BILIARY; LIVER NEOPLASMS; LIVER REGENERATION; TUMOR SUPPRESSOR PROTEIN P53; URSODEOXYCHOLIC ACID;

EID: 84864371596     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms13078882     Document Type: Review

References (229)

1. Hagey, L.R.; Crombie, D.L.; Espinosa, E.; Carey, M.C.; Igimi, H.; Hofmann, A.F. Ursodeoxycholic acid in the Ursidae: Biliary bile acids of bears, pandas, and related carnivores. J. Lipid. Res. 1993, 34, 1911-1917.
2. Hofmann, A.F. Pharmacology of ursodeoxycholic acid, an enterohepatic drug. Scand. J. Gastroenterol. 1994, 204, S1-S15.
3. Bachrach, W.H.; Hofmann, A.F. Ursodeoxycholic acid in the treatment of cholesterol cholelithiasis. Part I. Dig. Dis. Sci. 1982, 27, 737-761.
4. Roma, M.G.; Toledo, F.D.; Boaglio, A.C.; Basiglio, C.L.; Crocenzi, F.A.; Sánchez Pozzi, E.J. Ursodeoxycholic acid in cholestasis: Linking action mechanisms to therapeutic applications. Clin. Sci. (Lond.) 2011, 121, 523-544.
5. Leuschner, U.; Leuschner, M.; Sieratzki, J.; Kurtz, W.; Hübner, K. Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow-up. A pilot study. Dig. Dis. Sci. 1985, 30, 642-649.
6. Heathcote, E.J.; Cauch-Dudek, K.; Walker, V.; Bailey, R.J.; Blendis, L.M.; Ghent, C.N.; Michieletti, P.; Minuk, G.Y.; Pappas, S.C.; Scully, L.J. et al. The Canadian multicentre double blind randomized controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994, 19, 1149-1156.
7. Degott, C.; Zafrani, E.S.; Callard, P.; Balkau, B.; Poupon, R.E.; Poupon, R. Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression. Hepatology 1999, 29, 1007-1012.
8. Gong, Y.; Huang, Z.B.; Christensen, E.; Gluud, C. Ursodeoxycholic acid for primary biliary cirrhosis. Cochrane Database Syst. Rev. 2008, 16, CD000551.
9. Reichen, J. Review: Ursodeoxycholic acid does not reduce risk for mortality or liver transplantation in primary cirrhosis. ACP J. Club 2008, 148, 17.
10. Paediatric Formulary Committee. British National Formulary for Children; Pharmaceutical Press: London, UK, 2010.
11. Kotb, M.A. Review of a historical cohort: Ursodeoxycholic acid in extrahepatic biliary atresia. J. Pediatr. Surg. 2008, 43, 1321-1327.
12. Kotb, M.A. Ursodeoxycholic acid in neonatal hepatitis and infantile paucity of intrahepatic bile ducts: Review of a historical cohort. Dig. Dis. Sci. 2009, 54, 2231-2241.
13. Lindor, K.D.; Kowdley, K.V.; Luketic, V.A.C.; Harrison, M.E.; McCashland, T.; Befeler, A.S.; Harnois, D.; Jorgensen, R.; Petz, J.; Keach, J. et al. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology 2009, 50, 808-814.
14. Rudolph, G.; Gotthardt, D.; Kloeters-Plachky, P.; Rost, D.; Kulaksiz, H.; Stiehl, A. In PSC with dominant bile duct stenosis, IBD is associated with an increase of carcinomas and reduced survival. J. Hepatol. 2010, 53, 313-317.
15. Rudolph, G.; Gotthardt, D.N.; Kloeters-Plachky, P.; Kulaksiz, H.; Schirmacher, P.; Stiehl, A. In PSC with colitis treated with UDCA, most colonic carcinomas develop in the first years after the start of treatment. Dig. Dis. Sci. 2011, 56, 3624-3630.
16. Kuiper, E.M.; Hansen, B.E.; Adang, R.P.; van Nieuwkerk, C.M.; Timmer, R.; Drenth, J.P.; Spoelstra, P.; Brouwer, H.T.; Kuyvenhoven, J.P.; van Buuren, H.R.; Dutch PBC Study Group. Relatively high risk for hepatocellular carcinoma in patients with primary biliary cirrhosis not responding to ursodeoxycholic acid. Eur. J. Gastroenterol. Hepatol. 2010, 22, 1495-1502.
17. Leuschner, M.; Dietrich, C.F.; You, T.; Seidl, C.; Raedle, J.; Herrmann, G.; Ackermann, H.; Leuschner, U. Characterisation of patients with primary biliary cirrhosis responding to long term ursodeoxycholic acid treatment. Gut 2000, 46, 121-126.
18. Bhandari, B.M.; Bayat, H.; Rothstein, K.D. Primary biliary cirrhosis. Gastroenterol. Clin. North Am. 2011, 40, 373-86, viii.
19. Burnat, G., Majka, J.; Konturek, P.C. Bile acids are multifunctional modulators of the Barrett's carcinogenesis. J. Physiol. Pharmacol. 2010, 61, 185-192.
20. Material Safety Data Sheet: Ursodiol MSDS. 2010. Available online: http://www.sciencelab.com/xMSDS-Ursodiol-9925395 (accessed on 13 June 2010).
21. Nie, B.; Park, H.M.; Kazantzis, M.; Lin, M.; Henkin, A.; Ng, S.; Song, S.; Chen, Y.; Tran, H.; Lai, R. et al. Specific bile acids inhibit hepatic fatty acid uptake. Hepatology 2012, 24, doi:10.1002/hep.25797.
22. Perez, M.J.; Briz, O. Bile-acid-induced cell injury and protection. World J. Gastroenterol. 2009, 15, 1677-1689.
23. Iaizzo, P.A.; Laske, T.G.; Harlow, H.J.; McClay, C.B.; Garshelis, D.L. Wound healing during hibernation by black bears (Ursus americanus) in the wild: Elicitation of reduced scar formation. Integr. Zool. 2012, 7, 48-60.
24. Schiedermaier, P.; Hansen, S.; Asdonk, D.; Brensing, K.; Sauerbruch, T. Effects of ursodeoxycholic acid on splanchnic and systemic hemodynamics. A double-blind, cross-over, placebo-controlled study in healthy volunteers. Digestion 2000, 61, 107-112.
25. Nair, P.; Turjman, N. Role of bile acids and neutral sterols in familial cancer syndromes of the colon. Dis. Colon Rectum 1983, 26, 629-632.
26. Sinakos, E.; Marschall, H.-U.; Kowdley, K.V.; Befeler, A.; Keach, J.; Lindor, K. Bile acid changes after high-dose ursodeoxycholic acid treatment in primary sclerosing cholangitis: Relation to disease progression. Hepatology 2010, 52, 197-203.
27. Fedorowski, T.; Salen, G.; Tint, G.S.; Mosbach, E. Transformation of chenodeoxycholic acid and ursodeoxycholic acid by human intestinal bacteria. Gastroenterology 1979, 77, 1068-1073.
28. Bazzoli, F.; Fromm, H.; Sarva, R.P.; Sembrat R.F.; Ceryak, S. Comparative formation of lithocholic acid from chenodeoxycholic and ursodeoxycholic acids in the colon. Gastroenterology 1982, 83, 753-760.
29. Thistle, J.L.; Larusso, N.F.; Hofmann, A.F.; Turcotte, J.; Carlson, G.L.; Ott, B.J. Differing effects of ursodeoxycholic or chenodeoxycholic acid on biliary cholesterol saturation and bile acid metabolism in man. A dose-response study. Dig. Dis. Sci. 1982, 27, 161-168.
30. Angulo, P. Use of ursodeoxycholic acid in patients with liver disease. Curr. Gastroenterol. Rep. 2002, 4, 37-44.
31. Guyot, C.; Combe, C.; Balabaud, C.; Bioulac-Sage, P.; Desmoulière, A. Fibrogenic cell fate during fibrotic tissue remodeling observed in rat and human cultured liver slices. J. Hepatol. 2007, 46, 142-150.
32. Hansell, C.; Nibbs, R. Professional and part-time chemokine decoys in the resolution of inflammation. Sci. STKE 2007, 384, pe18.
33. Brenner, D.A. Molecular pathogenesis of liver fibrosis. Trans. Am. Clin. Climatol. Assoc. 2009, 120, 361-368.
34. Bakkenist, C.J.; Kastan, M.B. DNA damage activates ATM through intermolecular autophosphorylation and dimmer dissociation. Nature 2003, 421, 499-506.
35. Jung, D.; Alt, F.W. Unraveling V(D)J recombination; insights into gene regulation. Cell 2004, 116, 299-311.
36. Braig, M.; Schmitt, C.A. Oncogene-induced senescence: Putting the brakes on tumor development. Cancer Res. 2006, 66, 2881-2884.
37. Campisi, J.; d'Adda di Fagagna, F. Cellular senescence: When bad things happen to good cells. Rev. Mol. Cell. Biol. 2007, 8, 729-740.
38. Lynch, M.D. How does cellular senescence prevent cancer? DNA Cell Biol. 2006, 25, 69-78.
39. Li, M.O.; Sarkisian, M.R.; Mehal, W.Z.; Rakic, P.; Flavell, R.A. Phosphatidylserine receptor is required for clearance of apoptotic cells. Science 2003, 302, 1560-1563.
40. Powell, A.A.; Akare, S.; Qi, W.; Herzer, P.; Jean-Louis, S.; Feldman, R.A.; Martinez, J.D. Resistance to ursodeoxycholic acid-induced growth arrest can also result in resistance to deoxycholic acid-induced apoptosis and increased tumorgenicity. BMC Cancer 2006, 6, doi:10.1186/1471-2407-6-219.
41. Solá, S.; Aranha, M.M.; Steer, C.J.; Rodrigues, C.M. Game and players: Mitochondrial apoptosis and the therapeutic potential of ursodeoxycholic acid. Curr. Issues Mol. Biol. 2007, 9, 123-138.
42. Castro, R.E.; Amaral, J.D.; Solá, S.; Kren, B.T.; Steer, C.J.; Rodrigues, C.M. Differential regulation of cyclin D1 and cell death by bile acids in primary rat hepatocytes. Am. J. Physiol. Gastrointest. Liver Physiol. 2007, 293, G327-G334.
43. Sola, S.; Ma, X.; Castro, R.E.; Kren, B.T.; Steer, C.J.; Rodrigues, C.M. Ursodeoxycholic acid modulates E2F-1 and p53 expression through a caspase-independent mechanism in transforming growth factor beta1-induced apoptosis of rat hepatocytes. J. Biol. Chem. 2003, 278, 48831-48838.
44. Im, E.; Martinez, J.D. Ursodeoxycholic acid (UDCA) can inhibit deoxycholic acid (DCA)-induced apoptosis via modulation of EGFR/Raf-1/ERK signaling in human colon cancer cells. J. Nutr. 2004, 134, 483-486.
45. Rodrigues, C.M.; Fan, G.; Wong, P.Y.; Kren, B.T.; Steer, C.J. Ursodeoxycholic acid may inhibit deoxycholic acid-induced apoptosis by modulating mitochondrial transmembrane potential and reactive oxygen species production. Mol. Med. 1998, 4, 165-178.
46. Koh, H.; Lee, K.H.; Kim, D.; Kim, S.; Kim, J.W.; Chung, J. Inhibition of Akt and its anti-apoptotic activities by tumor necrosis factor-induced protein kinase C-related kinase 2 (PRK2) cleavage. J. Biol. Chem. 2000, 275, 34451-34458.
47. Akare, S.; Jean-Louis, S.; Chen, W.; Wood, D.J.; Powell, A.A.; Martinez, J.D. Ursodeoxycholic acid modulates histone acetylation and induces differentiation and senescence. Int. J. Cancer 2006, 119, 2958-2969.
48. Rodrigues, C.M.; Fan, G.; Ma, X.; Kren, B.T.; Steer, C.J. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J. Clin. Invest. 1998, 101, 2790-2799.
49. Trauner, M.; Graziadei, I.W. Review article: Mechanisms of action and therapeutic applications of ursodeoxycholic acid in chronic liver diseases. Aliment. Pharmacol. Ther. 1998, 13, 979-996.
50. Lazaridis, K.N.; Gores, G.J.; Lindor, K.D. Ursodeoxycholic acid mechanisms of action and clinical use in hepatobiliary disorders. J. Hepatol. 2010, 35, 134-146.
51. Fickert, P.; Trauner, M.; Fuchsbichler, A.; Stumptner, C.; Zatloukal, K.; Denk, H. Cytokeratins as targets for bile acid-induced toxicity. Am. J. Pathol. 2002, 160, 491-599.
52. Martinez-Diez, M.C.; Serrano, M.A.; Monte, M.J.; Marin, J.J. Comparison of the effects of bile acids on cell viability and DNA synthesis by rat hepatocytes in primary culture. Biochim. Biophys. Acta 2000, 1500, 153-160.
53. Popov, Y.; Sverdlov, D.Y.; Bhaskar, K.R.; Sharma, A.K.; Millonig, G.; Patsenker, E.; Krahenbuhl, S.; Krahenbuhl, L.; Schuppan, D. Macrophage-mediated phagocytosis of apoptotic cholangiocytes contributes to reversal of experimental biliary fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol. 2010, 298, G323-G334.
54. Garewal, H.; Bernstein, H.; Bernstein C.; Sampliner, R.; Payne, C. Reduced bile acid-induced apoptosis in "normal" colorectal mucosa: A potential biological marker for cancer risk. Cancer Res. 1996, 56, 1480-1483.
55. Abate, N.; Carubbi, F.; Bozzoli, M.; Bertolotti, M.; Farah, I.; Rosi, A.; Carulli, N. Effect of chenodeoxycholic acid and ursodeoxycholic acid administration on acyl-CoA: Cholesterol acyltransferase activity in human liver. Ital. J. Gastroenterol. 1994, 26, 287-293.
56. Das, S.; Chakraborty, S.; Basu, A. Critical role of lipid rafts in virus entry and activation of phosphoinositide 3'kinase/Akt signaling during early stages of Japanese encephalitis virus infection in neural stem/progenitor cells. J. Neurochem. 2010, 115, 537-549.
57. Pontes Soares, C.; Portilho, D.M.; da Silva Sampaio, L.; Einicker-Lamas, M.; Morales, M.M.; Costa, M.L.; Dos Santos Mermelstein, C. Membrane cholesterol depletion by methyl-beta-cyclodextrin enhances the expression of cardiac differentiation markers. Cells Tissues Organs 2010, 192, 187-199.
58. Weber, P.; Wagner, M.; Schneckenburger, H. Fluorescence imaging of membrane dynamics in living cells. J. Biomed. Opt. 2010, 15, 046017.
59. Smith, L.L. Another cholesterol hypothesis: Cholesterol as antioxidant. Free Radic. Biol. Med. 1991, 11, 47-61.
60. DuSell, C.D.; Nelson, E.R.; Wang, X.; Abdo, J.; Mödder, U.I.; Umetani, M.; Gesty-Palmer, D.; Javitt, N.B.; Khosla, S.; McDonnell, D.P. The endogenous selective estrogen receptor modulator 27-hydroxycholesterol is a negative regulator of bone homeostasis. Endocrinology 2010, 151, 3675-3685.
61. Galluzzi, L.; Morselli, E.; Kepp, O.; Vitale, I.; Rigoni, A.; Vacchelli, E.; Michaud, M.; Zischka, H.; Castedo M.; Kroemer, G. Mitochondrial gateways to cancer. Mol. Asp. Med. 2010, 31, 1-20.
62. Bouscarel, B.; Gettys, T.W.; Fromm, H.; Dubner, H. Ursodeoxycholic acid inhibits glucagon-induced cAMP formation in hamster hepatocytes: A role for PKC. Am. J. Physiol. Gastrointest. Liver Physiol. 1995, 268, G300-G310.
63. Bouscarel, B.; Matsuzaki, Y.; Le, M.; Gettys, T.W.; Fromm, H. Changes in G protein expression account for impaired modulation of hepatic cAMP formation after BDL. Am. J. Physiol. 1998, 274, G1151-G1159.
64. Peterson, T.C.; Slysz, G.; Isbrucker, R. The inhibitory effect of ursodeoxycholic acid and pentoxifylline on platelet derived growth factor-stimulated proliferation is distinct from an effect by cyclic AMP. Immunopharmacology 1998, 39, 181-191.
65. Amaral, J.D.; Castro, R.E.; Solá, S.; Steer, C.J.; Rodrigues, C.M. p53 is a key molecular target of ursodeoxycholic acid in regulating apoptosis. J. Biol. Chem. 2007, 282, 34250-34259.
66. Amaral, J.D.; Xavier, J.M.; Steer, C.J.; Rodrigues, C.M. Targeting the p53 Pathway of Apoptosis. Curr. Pharm. Des. 2010, 16, 2493-2503.
67. Yu, J.; Zhang, L. PUMA, a potent killer with or without p53. Oncogene 2008, 27, S71-S83.
68. Jeffers, J.R.; Parganas, E.; Lee, Y.; Yang, C.; Wang, J.; Brennan, J.; MacLean, K.H.; Han, J.; Chittenden, T.; Ihle, J.N. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. Cancer Cell 2003, 4, 321-328.
69. Hoffman, W.H.; Biade, S.; Zilfou, J.T.; Chen, J.; Murphy, M. Transcriptional repression of the anti-apoptotic survivin gene by wild type p53. J. Biol. Chem. 2002, 277, 3247-3257.
70. Gudkov, A.V.; Komarova, E.A. The role of p53 in determining sensitivity to radiotherapy. Nat. Rev. Cancer 2003, 3, 117-129.
71. Georgiev, P.; Dahm, F.; Graf, R.; Clavien, P.A. Blocking the path to death: Anti-apoptotic molecules in ischemia/reperfusion injury of the liver. Curr. Pharm. Des. 2006, 12, 2911-2921.
72. Joerger, A.C.; Fersht, A.R. Structural biology of the tumor suppressor p53. Annu. Rev. Biochem. 2008, 77, 557-582.
73. Park, I.H.; Kim, M.K.; Kim, S.U. Ursodeoxycholic acid prevents apoptosis of mouse sensory neurons induced by cisplatin by reducing P53 accumulation. Biochem. Biophys. Res. Commun. 2008, 377, 1025-1030.
74. Ji, W.J.; Qu, Q.; Jin, Y.; Zhao, L.; He, X.D. Ursodeoxycholic acid inhibits hepatocyte-like cell apoptosis by down-regulating the expressions of Bax and Caspase-3. Zhonghua Yi Xue Za Zhi 2009, 89, 2997-3001.
75. Albensi, B.C.; Mattson, M.P. Evidence for the involvement of TNF and NF-κB in hippocampal synaptic plasticity. Synapse 2000, 35, 151-159.
76. Gilmore, T.D. Introduction to NF-κB: Players, pathways, perspectives. Oncogene 2006, 25, 6680-6684.
77. Perkins, N.D. Integrating cell-signalling pathways with NF-κB and IKK function. Nat. Rev. Mol. Cell. Biol. 2007, 8, 49-62.
78. Miura, T.; Ouchida, R.; Yoshikawa, N.; Okamoto, K.; Makino, Y.; Nakamura, T.; Morimoto, C.; Makino, I.; Tanaka, H. Functional modulation of the glucocorticoid receptor and suppression of NF-kappaB-dependent transcription by ursodeoxycholic acid. J. Biol. Chem. 2001, 276, 47371-47378.
79. Garg, A.; Aggarwal, B.B. Nuclear transcription factor-kappaB as a target for cancer drug development. Leukemia 2002, 16, 1053-1068.
80. Sethi, G.; Sung, B.; Aggarwal, B.B. Nuclear factor-kappaB activation: From bench to bedside. Exp. Biol. Med. 2008, 233, 21-31.
81. Schuster, A.; Schilling, T.; De Laurenzi, V.; Koch, A.F.; Seitz, S.; Staib, F.; Teufel, A.; Thorgeirsson, S.S.; Galle, P.R.; Melino, G. et al. DeltaNp73beta is oncogenic in hepatocellular carcinoma by blocking apoptosis signaling via death receptors and mitochondria. Cell Cycle 2010, 9, 2629-2639.
82. Higuchi, H.; Grambihler, A.; Canbay, A.; Bronk, S.F.; Gores, G.J. Bile acids up-regulate death receptor 5/TRAIL-receptor 2 expression via a c-Jun N-terminal kinase-dependent pathway involving Sp1. J. Biol. Chem. 2004, 279, 51-60.
83. Choi, Y.H.; Im, E.O.; Suh, H.; Jin, Y.; Yoo, Y.H.; Kim, N.D. Apoptosis and modulation of cell cycle control by synthetic derivatives of ursodeoxycholic acid and chenodeoxycholic acid in human prostate cancer cells. Cancer Lett. 2003, 199, 157-167.
84. Im, E.; Akare, S.; Powell, A.; Martinez, J.D. Ursodeoxycholic acid can suppress deoxycholic acid-induced apoptosis by stimulating Akt/PKB-dependent survival signaling. Nutr. Cancer 2005, 51, 110-116.
85. Horowitz, N.S.; Hua, J.; Powell, M.A.; Gibb, R.K.; Mutch, D.G.; Herzog, T.J. Novel cytotoxic agents from an unexpected source: Bile acids and ovarian tumor apoptosis. Gynecol. Oncol. 2007, 107, 344-349.
86. Khare, S.; Mustafi, R.; Cerda, S.; Yuan, W.; Jagadeeswaran, S.; Dougherty, U.; Tretiakova, M.; Samarel, A.; Cohen, G.; Wang, J. et al. Ursodeoxycholic acid suppresses Cox-2 expression in colon cancer: Roles of Ras, p38, and CCAAT/enhancer-binding protein. Nutr. Cancer 2008, 60, 389-400.
87. Su, J.G.; Liao, P.J.; Huang, M.C.; Chu, W.C.; Lin, S.C.; Chang, Y.J. Aldo-keto reductase 1C is essential for 1-nitropyrene's but not for benzo[a]pyrene's induction of p53 phosphorylation and apoptosis. Toxicology 2008, 244, 257-270.
88. Wimmer, R.; Hohenester, S.; Pusl, T.; Denk, G.U.; Rust, C.; Beuers, U. Tauroursodeoxycholic acid exerts anticholestatic effects by a cooperative cPKC alpha-/PKA-dependent mechanism in rat liver. Gut 2008, 57, 1448-1454.
89. Andersson, Y.; Juell, S.; Fodstad, Ø. Downregulation of the antiapoptotic MCL-1 protein and apoptosis in MA-11 breast cancer cells induced by an anti-epidermal growth factor receptor-Pseudomonas exotoxin a immunotoxin. Int. J. Cancer 2004, 112, 475-483.
90. Rolo, A.P.; Palmeira, C.M.; Holy, J.M.; Wallace, K.B. Role of mitochondrial dysfunction in combined bile acid-induced cytotoxicity: The switch between apoptosis and necrosis. Toxicol. Sci. 2004, 79, 196-204.
91. Zollner, G.; Trauner, M. Nuclear receptors as therapeutic targets in cholestatic liver diseases. Br. J. Pharmacol. 2009, 156, 7-27.
92. Huang, J.; Plass, C.; Gerhauser, C. Cancer chemoprevention by targeting the epigenome. Curr. Drug Targets 2011, 12, 1925-1956.
93. Oike, T.; Ogiwara, H.; Torikai, K.; Nakano, T.; Yokota, J.; Kohno, T. Garcinol, a histone acetyltransferase inhibitor, radiosensitizes cancer cells by inhibiting non-homologous end joining. Int. J. Radiat. Oncol. Biol. Phys. 2012, in press.
94. Calmus, Y.; Gane, P.; Rouger, P.; Poupon, R. Hepatic expression of class I and class II histocompatibility complex molecules in primary biliary cirrhosis: Effect of ursodeoxycholic acid. Hepatology 1990, 11, 12-15.
95. Yoshikawa, M.; Tsujii, T.; Matsumura, K.; Yamao, J.; Matsumura, Y.; Kubo, R.; Fukui, H.; Ishizaka, S. Immunomodulatory effects of ursodeoxycholic acid on immune responses. Hepatology 1992, 16, 358-364.
96. Quist, R.G.; Ton-Nu, H.T.; Lillienau, J.; Hofmann, A.F.; Barrett, K.E. Activation of mast cells by bile acids. Gastroenterology 1991, 101, 446-456.
97. Solá, S.; Amaral, J.D.; Aranha, M.M.; Steer, C.J.; Rodrigues, C.M. Modulation of hepatocyte apoptosis: Cross-talk between bile acids and nuclear steroid receptors. Curr. Med. Chem. 2006, 13, 3039-3051.
98. Solá, S.; Amaral, J.D.; Castro, R.E.; Ramalho, R.M.; Borralho, P.M.; Kren, B.T.; Tanaka, H.; Steer, C.J.; Rodrigues, C.M. Nuclear translocation of UDCA by the glucocorticoid receptor is required to reduce TGF-beta1-induced apoptosis in rat hepatocytes. Hepatology 2005, 42, 925-934.
99. Weitzel, C.; Stark, D.; Kullmann, F.; Schölmerich, J.; Holstege, A.; Falk, W. Ursodeoxycholic acid induced activation of the glucocorticoid receptor in primary rat hepatocytes. Eur. J. Gastroenterol. Hepatol. 2005, 17, 169-177.
100. Amaral, J.D.; Solá, S.; Steer, C.J.; Rodrigues, C.M. Role of nuclear steroid receptors in apoptosis. Curr. Med. Chem. 2006, 16, 3886-3902.
101. Jacquemin, E.; Hermans, D.; Myara, A.; Habes, D.; Debray, D.; Hadchouel, M.; Sokal, E.M.; Bernard, O. Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis. Hepatology 1997, 25, 519-523.
102. Masferrer, J.L.; Seibert, K. Regulation of prostaglandin synthesis by glucocorticoids. Receptor 1994, 4, 25-30.
103. Goppelt-Struebe, M. Molecular mechanisms involved in the regulation of prostaglandin biosynthesis by glucocorticoids. Biochem. Pharmacol. 1997, 53, 1389-1395.
104. Ikegami, T.; Matsuzaki, Y.; Fukushima, S.; Shoda, J.; Olivier, J.L.; Bouscarel, B.; Tanaka, N. Suppressive effect of ursodeoxycholic acid on type IIA phospholipase A2 expression in HepG2 cells. Hepatology 2005, 41, 896-905.
105. Mitsuyoshi, H.; Nakashima, T.; Inaba, K.; Ishikawa, H.; Nakajima, Y.; Sakamoto, Y.; Matsumoto, M.; Okanoue, T.; Kashima, K. Ursodeoxycholic acid enhances glucocorticoid-induced tyrosine aminotransferase-gene expression in cultured rat hepatocytes. Biochem. Biophys. Res. Commun. 1997, 240, 732-736.
106. Luisi, B.F.; Xu, W.X.; Otwinowski, Z.; Freedman, L.P.; Yamamoto, K.R.; Sigler, P.B. Crystallographic analysis of the interaction of the glucocorticoid receptor with DNA. Nature 1991, 352, 497-505.
107. Savory, J.G.; Préfontaine, G.G.; Lamprecht, C.; Liao, M.; Walther, R.F.; Lefebvre, Y.A.; Haché, R.J. Glucocorticoid receptor homodimers and glucocorticoid-mineralocorticoid receptor heterodimers form in the cytoplasm through alternative dimerization interfaces. Mol. Cell. Biol. 2001, 21, 781-793.
108. Solá, S.; Castro, R.E.; Kren, B.T.; Steer, C.J.; Rodrigues, C.M. Modulation of nuclear steroid receptors by ursodeoxycholic acid inhibits TGF-beta1-induced E2F-1/p53-mediated apoptosis of rat hepatocytes. Biochemistry 2004, 43, 8429-8438.
109. Shi, Q.Y.; Kong, B.H.; Ma, K.D.; Zhang, X.L.; Jiang, S. Effects of ursodeoxycholic acid on the liver plasma membrane fluidity, hepatic glutathione concentration, hepatic estrogen receptors and progesterone receptors in pregnant rats with ethinylestradiol and progesterone induced intrahepatic cholestasis. Zhonghua Fu Chan Ke Za Zhi 2003, 38, 680-682. Abstract.
110. Rodrigues, C.M.; Ma, X.; Linehan-Stieers, C.; Fan, G.; Kren, B.T.; Steer, C.J. Ursodeoxycholic acid prevents cytochrome c release in apoptosis by inhibiting mitochondrial membrane depolarization and channel formation. Cell Death Differ. 1999, 6, 842-854.
111. Nishigaki, Y.; Ohnishi, H.; Moriwaki, H.; Muto, Y. Ursodeoxycholic acid corrects defective natural killer activity by inhibiting prostaglandin E2 production in primary biliary cirrhosis. Dig. Dis. Sci. 1996, 41, 1487-1493.
112. Guarino, M.P.; Carotti, S.; Morini, S.; Perrone, G.; Behar, J.; Altomare, A.; Alloni, R.; Caviglia, R.; Emerenziani, S.; Rabitti, C.; Cicala, M. Decreased number of activated macrophages in gallbladder muscle layer of cholesterol gallstone patients following ursodeoxycholic acid. Gut 2008, 57, 1740-1741.
113. Paolini, M.; Pozzetti, L.; Montagnani, M.; Potenza, G.; Sabatini, L.; Antelli, A.; Cantelli-Forti, G.; Roda, A. Ursodeoxycholic acid (UDCA) prevents DCA effects on male mouse liver via up-regulation of CYP [correction of CXP] and preservation of BSEP activities. Hepatology 2002, 36, 305-314.
114. Pemberton, P.W.; Aboutwerat, A.; Smith, A.; Warnes, T.W. Ursodeoxycholic acid in primary biliary cirrhosis improves glutathione status but fails to reduce lipid peroxidation. Redox. Rep. 2006, 11, 117-123.
115. Zollner, G.; Wagner, M.; Moustafa, T.; Fickert, P.; Silbert, D.; Gumhold, J.; Fuchsbichler, A.; Halilbasic, E.; Denk, H.; Marschall, H.U. et al. Coordinated induction of bile acid detoxification and alternative elimination in mice: Role of FXR-regulated organic solute transporter-alpha/beta in the adaptive response to bile acids. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 290, G923-G932.
116. Boyland, E.; Chasseaud, L.F. Enzymes catalysing conjugations of glutathione with alpha-beta-unsaturated carbonyl compounds. Biochem. J. 1968, 109, 651-661.
117. Boyland, E.; Chasseaud, L.F. Glutathione S-aralkyltransferase. Biochem. J. 1969, 115, 985-991.
118. Boyland, E.; Chasseaud, L.F. The role of glutathione and glutathione S-transferases in mercapturic acid biosynthesis. Adv. Enzymol. Relat. Areas. Mol. Biol. 1969, 32, 173-219.
119. Jakoby, W.B.; Ziegler, D.M. The enzymes of detoxication. J. Biol. Chem. 1990, 265, 20715-20718.
120. Ziegler, D.M.; Ansher, S.S.; Nagata, T.; Kadlubar, F.F.; Jakoby, W.B. N-methylation: Potential mechanism for metabolic activation of carcinogenic primary arylamines. Proc. Natl. Acad. Sci. USA 1988, 85, 2514-2517.
121. Ujhelly, O.; Ozvegy, C.; Várady, G.; Cervenak, J.; Homolya, L.; Grez, M.; Scheffer, G.; Roos, D.; Bates, S.E.; Váradi, A. et al. Application of a human multidrug transporter (ABCG2) variant as selectable marker in gene transfer to progenitor cells. Hum. Gene Ther. 2003, 14, 403-412.
122. Homolya, L.; Váradi, A.; Sarkadi, B. Multidrug resistance-associated proteins: Export pumps for conjugates with glutathione, glucuronate or sulfate. Biofactors 2003, 17, 103-114.
123. Commandeur, J.N.; Stijntjes, G.J.; Vermeulen, N.P. Enzymes and transport systems involved in the formation and disposition of glutathione S-conjugates. Role in bioactivation and detoxication mechanisms of xenobiotics. Pharmacol. Rev. 1995, 47, 271-330.
124. Fickert, P.; Zollner, G.; Fuchsbichler, A.; Stumptner, C.; Weiglein, A.H.; Lammert, F.; Marschall, H.U.; Tsybrovskyy, O.; Zatloukal, K.; Denk, H. et al. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology 2002, 123, 1238-1251.
125. Zollner, G.; Marschall, H.U.; Wagner, M.; Trauner, M. Role of nuclear receptors in the adaptive response to bile acids and cholestasis: Pathogenetic and therapeutic considerations. Mol. Pharm. 2006, 3, 231-251.
126. Mizuno, N.; Niwa, T.; Yotsumoto, Y.; Sugiyama, Y. Impact of drug transporter studies on drug discovery and development. Pharmacol. Rev. 2003, 55, 425-461.
127. Thornalley, P.J. The glyoxalase system: New developments towards functional characterization of a metabolic pathway fundamental to biological life. Biochem. J. 1990, 269, 1-11.
128. Sies, H. Oxidative stress: Oxidants and antioxidants. Exp. Physiol. 1997, 82, 291-295.
129. Joo, S.S.; Kang, H.C.; Won, T.J.; Lee, D.I. Ursodeoxycholic acid inhibits pro-inflammatory repertoires.; IL-1 beta and nitric oxide in rat microglia. Arch. Pharm. Res. 2003, 26, 1067-1073.
130. Joo, S.S.; Won, T.J.; Hwang, K.W.; Lee, D.I. Inhibition of iNOS expression via Ursodeoxycholic acid in murine microglial cell; BV-2 Cell Line. Immune Netw. 2005, 5, 45-49.
131. Joo, S.S.; Won, T.J.; Lee, D.I. Potential role of ursodeoxycholic acid in suppression of nuclear factor kappa B in microglial cell line (BV-2). Arch. Pharm. Res. 2004, 27, 954-960.
132. Parry, G.J.; Rodrigues, C.M.; Aranha, M.M.; Hilbert, S.J.; Davey, C.; Kelkar, P.; Low, W.C.; Steer, C.J. Safety.; tolerability.; and cerebrospinal fluid penetration of ursodeoxycholic Acid in patients with amyotrophic lateral sclerosis. Clin. Neuropharmacol. 2010, 33, 17-21.
133. Ramalho, R.M.; Viana, R.J.; Low, W.C.; Steer, C.J.; Rodrigues, C.M. Bile acids and apoptosis modulation: An emerging role in experimental Alzheimer's disease. Trends Mol. Med. 2008, 14, 54-62.
134. Ritter, M.R.; Banin, E.; Moreno, S.K.; Aguilar, E.; Dorrel, M.I.; Friedlander, M. Myeloid progenitors differentiate into microglia and promote vascular repair in a model of ischemic retinopathy. J. Clin. Invest. 2006, 116, 3266-3276.
135. Streit, W.J. Microglial senescence: Does the brain's immune system have an expiration date? Trends Neurosci. 2006, 29, 506-510.
136. Wee Yong, V. Inflammation in neurological disorders: A help or a hindrance? Neuroscientist 2010, 16, 408-420.
137. Gordo, A.C.; Falcão, A.S.; Fernandes, A.; Brito, M.A.; Silva, R.F.M.; Brites, D. Unconjugated bilirubin activates and damages microglia. J. Neurosci. Res. 2006, 84, 194-201.
138. Jantaratnotai, N.; Schwab, C.; Ryu, J.K.; McGeer, P.L.; McLarnon, J.G. Converging perturbed microvasculature and microglial clusters characterize alzheimer disease brain. Curr. Alzheimer Res. 2010, 7, 625-636.
139. Im, E.O.; Choi, Y.H.; Paik, K.J.; Suh, H.; Jin, Y.; Kim, KW.; Yoo, Y.H.; Kim, N.D. Novel bile acid derivatives induce apoptosis via a p53-independent pathway in human breast carcinoma cells. Cancer Lett. 2001, 163, 83-93.
140. Im, E.; Choi, S.H.; Suh, H.; Choi, Y.H.; Yoo, Y.H.; Kim, N.D. Synthetic bile acid derivatives induce apoptosis through a c-Jun N-terminal kinase and NF-kappaB-dependent process in human cervical carcinoma cells. Cancer Lett. 2005, 229, 49-57.
141. Pavek, P.; Merino, G.; Wagenaar, E.; Bolscher, E.; Novotna, M.; Jonker, J.W.; Schinkel, A.H. Human breast cancer resistance protein: Interactions with steroid drugs, hormones, the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, and transport of cimetidine. J. Pharmacol. Exp. Ther. 2005, 312, 144-152.
142. Fimognari, C.; Lenzi, M.; Cantelli-Forti, G.; Hrelia, P. Apoptosis and modulation of cell cycle control by bile acids in human leukemia T cells. Ann. N. Y. Acad. Sci. 2009, 1171, 264-269.
143. Hiramatsu, K.; Matsumoto, Y.; Miyazaki, M.; Tsubouchi, H.; Yamamoto, I.; Gohda, E. Inhibition of hepatocyte growth factor production in human fibroblasts by ursodeoxycholic acid. Biol. Pharm. Bull. 2005, 28, 619-624.
144. Zarnegar, R.; Michalopoulos, G.K.J. The many faces of hepatocyte growth factor: From hepatopoiesis to hematopoiesis. Cell Biol. 1995, 129, 1177-1180.
145. Matsumoto, K.; Nakamura, T. Hepatocyte growth factor (HGF) as a tissue organizer for organogenesis and regeneration. Biochem. Biophys. Res. Commun. 1997, 239, 639-644.
146. Yasuda, H.; Imai, E.; Shiota, A.; Fujise, N.; Morinaga, T.; Higashio, K. Antifibrogenic effect of a deletion variant of hepatocyte growth factor on liver fibrosis in rats. Hepatology 1996, 24, 636-642.
147. Mizuno, S.; Kurosawa, T.; Matsumoto, K.; Mizuno-Horikawa, Y.; Okamoto, M.; Nakamura, T. Hepatocyte growth factor prevents renal fibrosis and dysfunction in a mouse model of chronic renal disease. J. Clin. Invest. 1998, 101, 1827-1834.
148. Tsagarakis, N.J.; Drygiannakis, I.; Batistakis, A.G.; Kolios, G.; Kouroumalis, E.A. A concentration-dependent effect of ursodeoxycholate on apoptosis and caspases activities of HepG2 hepatocellular carcinoma cells. Eur. J. Pharmacol. 2010, 640, 1-7.
149. Ikegami, T.; Matsuzaki, Y.; Al Rashid, M.; Ceryak, S.; Zhang, Y.; Bouscarel, B. Enhancement of DNA topoisomerase I inhibitor-induced apoptosis by ursodeoxycholic acid. Mol. Cancer. Ther. 2006, 5, 68-79.
150. Kawato, Y.; Aonuma, M.; Hirota, Y.; Kuga, H.; Sato, K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res. 1991, 51, 4187-4191.
151. Fimognari, C.; Nüsse, M.; Cesari, R.; Cantelli-Forti, G.; Hrelia, P. Micronuclei induction, cell cycle delay and apoptosis as markers of cellular stress caused by ursodeoxycholic acid in human lymphocytes. Mutat. Res. 2001, 495, 1-9.
152. Norppa, H.; Falck, G.C. What do human micronuclei contain? Mutagenesis 2003, 18, 221-233.
153. Irifune, H.; Tsukazaki, N.; Watanabe, M.; Nonaka, S. The influence of ursodesoxycholic acid (URSO) on griseofulvin (GF)-induced protoporphyria. Nihon Hifuka Gakkai Zasshi 1991, 101, 813-817.
154. Kessel, D.; Caruso, J.A.; Reiners, J.J., Jr. Potentiation of photodynamic therapy by ursodeoxycholic acid. Cancer Res. 2000, 60, 6985-6988.
155. Rolo, A.P.; Palmeira, C.M.; Holy, J.M.; Wallace, K.B. Role of mitochondrial dysfunction in combined bile acid-induced cytotoxicity: The switch between apoptosis and necrosis. Toxicol. Sci. 2004, 79, 196-204.
156. Poropat, G.; Giljaca, V.; Stimac, D.; Gluud, C. Bile acids for liver-transplanted patients. Cochrane Database Syst. Rev. 2010, 3, CD005442.
157. Scharschmidt, B.F.; Lake, J.R. Hepatocellular bile acid transport and ursodeoxycholic acid hypercholeresis. Dig. Dis. Sci. 1989, 34, 5S-15S.
158. Katz, R.; Ducci, H.; Alessandri, H. Influence of cortisone and prednisolone on hyperbilirubinemia. J. Clin. Invest. 1957, 36, 1370-1374.
159. Ohkubo, H.; Okuda, K. The nicotinic acid test in constitutional conjugated hyperbilirubinemias and effects of corticosteroid. Hepatology 1984, 4, 1206-1208.
160. Giljaca, V.; Poropat, G.; Stimac, D.; Gluud, C. Glucocorticosteroids for primary sclerosing cholangitis. Cochrane Database Syst. Rev. 2010, 1, CD004036.
161. Propst, A.; Propst, T.; Zangerl, G.; Ofner, D.; Judmaier, G.; Vogel, W. Prognosis and life expectancy in chronic liver disease. Dig. Dis. Sci. 1995, 40, 1805-1815.
162. Wong, G.L.; Chan, H.L. Predictors of treatment response in chronic hepatitis B. Drugs 2009, 69, 2167-2177.
163. Sangfelt, P.; von Sydow, M.; Uhnoo, I.; Weiland, O.; Lindh, G.; Fischler, B.; Lindgren, S.; Reichard, O. Serum ALT levels as a surrogate marker for serum HBV DNA levels in HBeAg-negative pregnant women. Scand. J. Infect. Dis. 2004, 36, 182-185.
164. Prestileo, T.; Mazzola, G.; di Lorenzo, F.; Colletti, P.; Vitale, F.; Ferraro, D.; di Stefano, R.; Cammà, C.; Craxì, A. Response-adjusted alpha-interferon therapy for chronic hepatitis C in HIV-infected patients. Int. J. Antimicrob. Agents 2000, 16, 373-378.
165. Thompson, P.A.; Wertheim, B.C.; Roe, D.J.; Ashbeck, E.L.; Jacobs, E.T.; Lance, P.; Martinez, M.E.; Alberts, D.A. Gender modifies the effect of ursodeoxycholic acid in a randomized controlled trial in colorectal adenoma patients. Cancer Prev. Res. (Phila.) 2009, 2, 1023-1030.
166. Sørensen, H.T.; Thulstrup, A.M.; Mellemkjar, L.; Jepsen, P.; Christensen, E.; Olsen, J.H.; Vilstrup, H. Long-term survival and cause-specific mortality in patients with cirrhosis of the liver: A nationwide cohort study in Denmark. J. Clin. Epidemiol. 2003, 56, 88-93.
167. Wachtel, M.S.; Zhang, Y.; Kaye, K.E.; Chiriva-Internati, M.; Frezza, E.E. Increased age, male gender, and cirrhosis, but not steatosis or a positive viral serology, negatively impact the life expectancy of patients who undergo liver biopsy. Dig. Dis. Sci. 2007, 52, 2276-2281.
168. Normann, A.; Badur, S.; Onel, D.; Kilic, A.; Sidal, M.; Larouzé, B.; Massari, V.; Müller, J.; Flehmig, B. Acute hepatitis A virus infection in Turkey. J. Med. Virol. 2008, 80, 785-790.
169. Migita, K.; Watanabe, Y.; Jiuchi, Y.; Nakamura, Y.; Saito, A.; Yagura, M.; Morimoto, H.; Shimada, M.; Mita, E.; Hijioka, T. et al. Evaluation of risk factors for the development of cirrhosis in autoimmune hepatitis: Japanese NHO-AIH prospective study. J. Gastroenterol. 2011, 46, S56-S62.
170. Sanai, F.M.; Benmousa, A.; Al-Hussaini, H.; Ashraf, S.; Alhafi, O.; Abdo, A.A.; Alameri, H.F.; Akbar, H.O.; Bzeizi, K.I. Is serum alanine transaminase level a reliable marker of histological disease in chronic hepatitis C infection? Liver Int. 2008, 28, 1011-1018.
171. Ali, N.; Moiz, B.; Moatter, T.; Ahmed, S.; Adil, S.N.; Khurshid, M. Correlation of hepatitis C RNA and serum alanine aminotransferase in hepatitis B and C seronegative healthy blood donors. Indian J. Pathol. Microbiol. 2010, 53, 480-485.
172. Thomson, E.C.; Fleming, V.M.; Main, J.; Klenerman, P.; Weber, J.; Eliahoo, J.; Smith, J.; McClure, M.O.; Karayiannis, P. Predicting spontaneous clearance of acute hepatitis C virus in a large cohort of HIV-1-infected men. Gut 2010, 60, 837-845.
173. Chen, W.; Gluud, C. Bile acids for primary sclerosing cholangitis. Cochrane Database Syst. Rev. 2003, 2, CD003626.
174. Cheng, K.; Ashby, D.; Smyth, R. Ursodeoxycholic acid for cystic fibrosis-related liver disease. Cochrane Database Syst. Rev. 2000, 2, CD000222.
175. Goulis, J.; Leandro, G.; Burroughs, A.K. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: A meta-analysis. Lancet 1999, 354, 1053-1060.
176. Combes, B.; Luketic, V.A.; Peters, M.G.; Zetterman, R.K.; Garcia-Tsao, G.; Munoz, S.J.; Lin, D.; Flye, N.; Carithers, R.L., Jr. Prolonged follow-up of patients in the U.S. multicenter trial of ursodeoxycholic acid for primary biliary cirrhosis. Am. J. Gastroenterol. 2004, 99, 264-268.
177. Combes, B.; Carithers, R.L., Jr.; Maddrey, W.C.; Lin, D.; McDonald, M.F.; Wheeler, D.E.; Eigenbrodt, E.H.; Muñoz, S.J.; Rubin, R.; Garcia-Tsao, G. et al. A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995, 22, 759-766.
178. Corpechot, C.; Carrat, F.; Bonnand, A.M.; Poupon, R.E.; Poupon, R. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 2000, 32, 1196-9.
179. Charatcharoenwitthaya, P.; Pimentel, S.; Talwalkar, J.A.; Enders, F.T.; Lindor, K.D.; Krom, R.A.; Wiesner, R.H. Long-term survival and impact of ursodeoxycholic acid treatmentfor recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl. 2007, 13, 1236-1245.
180. Parés, A.; Caballería, L.; Rodés, J.; Bruguera M.; Rodrigo, L.; García-Plaza, A.; Berenguer, J.; Rodríguez-Martínez, D.; Mercader, J.; Velicia, R. Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: Results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the Liver. J. Hepatol. 2000, 32, 561-566.
181. Shi, J.; Wu, C.; Lin, Y.; Chen, Y.X.; Zhu, L.; Xie, W.F. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: A meta-analysis of randomized controlled trials. Am. J. Gastroenterol. 2006, 101, 1529-1538.
182. Hohenester, S.; Oude-Elferink, R.P.; Beuers, U. Primary biliary cirrhosis. Semin. Immunopathol. 2009, 31, 283-307.
183. Roll, J.; Boyer, J.L.; Barry, D.; Klatskin, G. The prognostic importance of clinical and histological features in asymptomatic and symptomatic primary biliary cirrhosis. N. Engl. J. Med. 1983, 308, 1-7.
184. Springer, J.; Cauch-Dudek, K.; O'Rourke, K.; Wanless, I.R.; Heathcote, E.J. Asymptomatic primary biliary cirrhosis: A study of its natural history and prognosis. Am. J. Gstroenterol. 1999, 94, 47-53.
185. Kim, W.R.; Lindor, K.D.; Locke, G.R.; Thermeau, T.M.; Homburger, H.A.; Batts, K.P.; Yawn, B.P.; Petz, J.L.; Melton, 3rd.L.J.; Dickson, E.R. Epidemiology and natural history of primary biliary cirrhosis in a US community. Gastroenterology 2000, 119, 1631-1636.
186. Balasubramaniam, K.; Grambsch, P.M.; Wiesner, R.H.; Lindor, K.D.; Dickson, E.R. Diminished survival in asymptomatic primary biliary cirrhosis: A prospective study. Gastroenterology 1990, 98, 1567-1571.
187. Mahl, T.C.; Shockcor, W.; Boyer, J.L. Primary biliary cirrhosis: Survival of a large cohort of symptomatic and asymptomatic patients followed for 24 years. J. Hepatol. 1994, 20, 707-713.
188. Dickson, E.R.; Fleming, T.R.; Wiesner, R.H.; Baldus, W.P.; Fleming, C.R.; Ludwig, J.; McCall, J.T. Trial of penicillamine in advanced primary biliary cirrhosis. N. Engl. J. Med. 1985, 312, 1011-1015.
189. Feldstein, A.E.; Perrault, J.; El-Youssif, M.; Lindor, K.D.; Freese, D.K.; Angulo, P. Primary sclerosing cholangitis in children: A long-term follow-up study. Hepatology 2003, 38, 210-217.
190. Prince, M.; Christensen, E.; Gluud, C. Glucocorticosteroids for primary biliary cirrhosis. Cochrane Database Syst. Rev. 2005, 2, CD003778.
191. Van Hoogstraten, H.J.; Wolfhagen, F.H.; van de Meeberg, P.C.; Kuiper, H.; Nix, G.A.; Becx, M.C.; Hoek, A.C.; van Houte, D.P.; Rijk, M.C.; Salemans, J.M. et al. Ursodeoxycholic acid therapy for primary sclerosing cholangitis: Results of a 2-year randomized controlled trial to evaluate single versus multiple daily doses. J. Hepatol. 1998, 29, 417-423.
192. Lindor, K.D. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis Ursodeoxycholic Acid Study Group. N. Engl. J. Med. 1997, 336, 691-695.
193. Kader, H.H.; Balistreri, W.F. Cholestasis. In Nelson Textbook of Pediatrics, 17th ed.; Beherman, R.E., Kleigmen, R.M., Jenson, H.B., Eds.; WB Saunders: Philadelphia, PA, USA, 2004; pp. 1314-1319.
194. Fickert, P.; Fuchsbichler, A.; Marschall, H.U.; Wagner, M.; Zollner, G.; Krause, R.; Zatloukal, K.; Jaeschke, H.; Denk, H.; Trauner, M. Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice. Am. J. Pathol. 2006, 168, 410-422.
195. Takikawa, H.; Beppu, T.; Seyama, Y.; Obinata, K.; Nittono, H. Serum concentration of glucuronidated and sulfated bile acids in children with cholestasis. Biochem. Med. 1985, 33, 381-386.
196. Shoda, J.; Mahara, R.; Osuga, T.; Mahara, R.; Osuga, T.; Ohnishi, S.; Miyazaki, H.; Tanaka, N.; Matsuzaki, Y. Similarity of unusual bile acids in human umbilical cord blood and amniotic fluid from newborns and in sera and urine from adult patients with cholestatic liver diseases. J. Lipid Res. 1988, 29, 847-858.
197. Hofmann, A.F. Detoxification of lithocholic acid, a toxic bile acid relevance to drug hepatotoxicity. Drug Metab. Rev. 2004, 36, 703-722.
198. Chen, W.; Liu, J.P.; Gluud, C. Bile acids for viral hepatitis. Cochrane Database Syst. Rev. 2007, 4, CD003181.
199. Desmond, C.P.; Wilson, J.; Bailey, M.; Clark, D.; Roberts, S.K. The benign course of liver disease in adults with cystic fibrosis and the effect of ursodeoxycholic acid. Liver Int. 2007, 27, 1402-1408.
200. Feigelson, J.; Anagnostopoulos C.; Poquet, M.; Pecau, Y.; Munck, A.; Navarro, J. Liver cirrhosis in cystic fibrosis--therapeutic implications and long term follow up. Arch. Dis. Child. 1993, 68, 653-657.
201. Curry, M.P.; Hegarty, J.E. The gallbladder and biliary tract in cystic fibrosis. Curr. Gastroenterol. Rep. 2005, 7, 147-153.
202. Colombo, C.; Battezzati, P.M.; Crosignani, A.; Assaisso, M.; Ronchi, M.; Giunta, A. Effects of taurine and ursodeoxycholic acid on liver function tests in patients with cystic fibrosis. Acta Univ. Carol. Med. (Praha) 1990, 36, 148-151.
203. Cotting, J.; Lentze, M.J.; Reichen, J. Effects of ursodeoxycholic acid treatment on nutrition and liver function in patients with cystic fibrosis and longstanding cholestasis. Gut 1990, 31, 918-921.
204. Merli, M.; Bertasi, S.; Servi, R.; Diamanti, S.; Martino, F.; de Santis, A.; Goffredo, F.; Quattrucci, S.; Antonelli, M.; Angelico, M. Effect of a medium dose of ursodeoxycholic acid with or without taurine supplementation on the nutritional status of patients with cystic fibrosis: A randomized, placebo-controlled, crossover trial. J. Pediatr. Gastroenterol. Nutr. 1994, 19, 198-203.
205. Brigman, C.; Feranchak, A. Liver involvement in cystic fibrosis. Curr. Treat. Options Gastroenterol. 2006, 9, 484-496.
206. Colombo, C.; Bertolini, E.; Assaisso, M.L.; Bettinardi, N.; Giunta, A.; Podda, M. Failure of ursodeoxycholic acid to dissolve radiolucent gallstones in patients with cystic fibrosis. Acta Paediatr. 1993, 82, 562-565.
207. Trauner, M.; Fickert, P.; Halilbasic, E.; Moustafa, T. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases. Wien. Med. Wochenschr. 2008, 158, 542-548.
208. Orlando, R.; Azzalini, L.; Orando, S.; Lirussi, F. Bile acids for non-alcoholic fatty liver disease and/or steatohepatitis. Cochrane Database Syst. Rev. 2007, 1, CD005160.
209. Leuschner, U.F.; Lindenthal, B.; Herrmann, G.; Arnold, J.C.; Rössle, M.; Cordes, H.J.; Zeuzem, S.; Hein, J.; Berg, T.; NASH Study Group. High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: A double-blind, randomized, placebo-controlled trial. Hepatology 2010, 52, 472-479.
210. Di Ciaula, A.; Wang, D.Q.; Wang, H.H.; Bonfrate, L.; Portincasa, P. Targets for current pharmacologic therapy in cholesterol gallstone disease. Gastroenterol. Clin. North Am. 2010, 39, 245-264, viii-ix.
211. Alberts, D.S.; Martínez M.E.; Hess, L.M.; Einspahr, J.G.; Green, S.B.; Bhattacharyya, A.K.; Guillen, J.; Krutzsch, M.; Batta, A.K.; Salen, G. et al. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. J. Natl. Cancer Inst. 2005, 97, 846-853.
212. Quesada, B.M.; Kohan, G.; Roff, H.E.; Canullán, C.M.; Chiappetta Porras, L.T. Management of gallstones and gallbladder disease in patients undergoing gastric bypass. World J. Gastroenterol. 2010, 16, 2075-2079.
213. Ministry of Health and Welfare (MHW). Pharmaceuticals and Medical Devices Safety Information (Summary) No. 162. MHW: Tokyo, Japan, 27 September 2000.
214. Mayo, M.J. Patients and patience: The pitfalls of primary biliary cirrhosis trials. Nat. Clin. Pract. Gastroenterol. Hepatol. 2005, 2, 552-553.
215. Lo, S.K.; Fleming, K.A.; Chapman, R.W. A 2-year follow-up study of anti-neutrophil antibody in primary sclerosing cholangitis: Relationship to clinical activity, liver biochemistry and ursodeoxycholic acid treatment. J. Hepatol. 1994, 21, 974-978.
216. Floreani, A.; Caroli, D.; Variola, A.; Rizzotto, E.R.; Antoniazzi, S.; Chiaramonte, M.; Cazzagon, N.; Brombin, C.; Salmaso, L.; Baldo, V. A 35-year follow-up of a large cohort of patients with primary biliary cirrhosis seen at a single centre. Liver Int. 2011, 31, 361-368.
217. Nash, K.L.; Allison, M.E.; McKeon, D.; Lomas, D.J.; Haworth, C.S.; Bilton, D.; Alexander, G.J. A single centre experience of liver disease in adults with cystic fibrosis 1995-2006. J. Cyst. Fibros. 2008, 7, 252-257.
218. Siano, M.; de Gregorio, F.; Boggia, B.; Sepe, A.; Ferri, P.; Buonpensiero, P.; di Pasqua, A.; Raia, V. Ursodeoxycholic acid treatment in patients with cystic fibrosis at risk for liver disease. Dig. Liver Dis. 2010, 42, 428-431.
219. Lamontagne, J.; Pinkerton, M.; Block, T.M.; Lu, X. Hepatitis B and hepatitis C virus replication upregulates serine protease inhibitor Kazal, resulting in cellular resistance to serine protease-dependent apoptosis. J. Virol. 2010, 84, 907-917.
220. Li, J.C.; Yang, X.R.; Sun, H.X.; Xu, Y.; Zhou, J.; Qiu, S.J.; Ke, A.W.; Cui, Y.H.; Wang, Z.J.; Wang, W.M. et al. Up-regulation of Krüppel-Like factor 8 promotes tumor invasion and indicates poor prognosis for hepatocellular carcinoma. Gastroenterology 2010, 139, 2146-2157.
221. Wang, H.C.; Chung, P.J.; Wu, C.H.; Lan, K.P.; Yang, M.Y.; Wang, C.J. Solanum nigrum L. polyphenolic extract inhibits hepatocarcinoma cell growth by inducing G2/M phase arrest and apoptosis. J. Sci. Food Agric. 2011, 91, 178-185.
222. De Marco, G.; Sordino, D.; Bruzzese, E.; di Caro, S.; Mambretti, D.; Tramontano, A.; Colombo, C.; Simoni, P.; Guarino, A. Early treatment with ursodeoxycholic acid for cholestasis in children on parenteral nutrition because of primary intestinal failure. Aliment. Pharmacol. Ther. 2006, 24, 387-394.
223. Grattagliano, I.; Bonfrate, L.; Diogo, C.V.; Wang, H.H.; Wang, D.Q.; Portincasa, P. Biochemical mechanisms in drug-induced liver injury: Certainties and doubts. World J. Gastroenterol. 2009, 15, 4865-4876.
224. Barouki, R. Linking long-term toxicity of xeno-chemicals with short-term biological adaptation. Biochimie 2010, 92, 1222-1226.
225. Sainis, I.; Fokas, D.; Vareli, K.; Tzakos, A.G.; Kounnis, V.; Briasoulis, E. Cyanobacterial cyclopeptides as lead compounds to novel targeted cancer drugs. Mar. Drugs 2010, 8, 629-657.
226. Chapman, R.W. Primary sclerosing cholangitis: What is the role of ursodeoxycholic acid in therapy for PSC? Nat. Rev. Gastroenterol. Hepatol. 2010, 7, 74-75.
227. Lindor, K.; Rakela, J.; Fung, J. Conflict of interest policy. Hepatology 2008, 47, 1.
228. Makino, I.; Nakagawa, S. Changes in biliary lipid and biliary bile acid composition in patients after administration of ursodeoxycholic acid. J. Lipid Res. 1978, 19, 723-728.
229. Verma, A.; Jazrawi, R.P.; Ahmed, H.A.; Northfield, T.C. Prescribing habits in primary biliary cirrhosis: A national survey. Eur. J. Gastroenterol. Hepatol. 1999, 11, 817-820.